Abstract
The T-cell mediated autoimmune process that destroys pancreatic β cells in type 1 diabetes (T1D) is a complex phenotype influenced by multiple genetic and environmental factors. Human leukocyte antigen (HLA) accounts for about half of the genetic susceptibility, through a large variety of protective and predisposing haplotypes. Other important loci associated with T1D, with much smaller effects than HLA, include the insulin variable number of tandem repeats, PTPN22, and CTLA-4. Detecting the association and confirming it beyond doubt is only the first step. Identifying the functional variant from among a block of polymorphisms in tight linkage disequilibrium and determining its biological consequences can be an even more challenging task. It is hoped that the identification of additional loci and functional analysis of known ones, no matter how small each individual effect is, will provide: (1) pathophysiological insights necessary for the development of preventive interventions; (2) risk prediction to identify individuals that can benefit from them, and (3) potentially, identification of distinct subgenotypes, with different immune dysregulation pathways leading to the common disease phenotype that may respond to different preventive interventions.
References
1.
Kyvik KO, Green A, Beck-Nielsen H: Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. Br Med J 1995;311:913–917.
2.
Risch N: Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 1987;40:1–14.
3.
Davies JL, Kawaguchi Y, Bennett ST, Copeman JB, Cordell HJ, Pritchard LE, Reed PW, Gough SCL, Jenkins SC, Palmer SM, Balfour KM, Rowe B, Farrall M, Barnett AH, Bain SC, Todd JA: A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994;371:130–136.
4.
Cox NJ, Wapelhorst B, Morrison VA, Johnson L, Pinchuk, L, Spielman RS, Todd JA, Concannon P: Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. Am J Hum Genet 2001;69:820–830.
5.
Tuomilehto J, Karvonen M, Pitkaniemi J, Virtala E, Kohtamaki K, Toivanen L, Tuomilehto-Wolf E, The Finnish Childhood Type I Diabetes Registry Group: Record-high incidence of Type I (insulin-dependent) diabetes mellitus in Finnish children. Diabetologia 1999;42:655–660.
6.
Knip M, Akerblom HK: Environmental factors in the pathogenesis of type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999;107:S93–S100.
7.
Ellis TM, Atkinson MA: Early infant diets and insulin-dependent diabetes. Lancet 1996;347:1464–1465.
8.
Dahlquist GG: Viruses and other perinatal exposures as initiating events for beta-cell destruction. Ann Med 1997;29:413–417.
9.
Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, Roep BO: Development of type 1 diabetes despite severe hereditary B-cell deficiency. N Engl J M 2001;345:1036–1040.
10.
Winter WE, Harris N, Schatz D: Immunological markers in the diagnosis and prediction of autoimmune Type 1a diabetes. Clin Diabetes 2002;20:183–191.
11.
Nerup J, Platz P, Andersen OO, Christy M, Lyngsoe J, Poulsen JE, Ryder LP, Thomsen M, Nielsen LS, Svejgaard A: HLA antigens and diabetes mellitus. Lancet 1974;304:864–866.
12.
Cudworth AG, Woodrow JC: Evidence for HLA linked genes in ‘juvenile’ diabetes mellitus. Br Med J 1975;3:133–135.
13.
Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. Science 2002;296:2225–2229.
14.
Fain PR, Eisenbarth GS: Type 1 Diabetes, Autoimmunity, and the MHC; in Lowe WL Jr (ed): Genetics of DiabetesMellitus. Norwell, MA, Kluwer Academic Publishers, 2001, pp 43–63.
15.
Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA: The role of HLA class II genes in insulin-dependent diabetes melli tus – molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996;59:1134–1148.
16.
Pugliese A, Gianani R, Moromisato R, et al: 1995 HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody positive first degree relatives of patients with insulin-dependent diabetes. Diabetes 1995;44:608–613.
17.
Todd JA, Bell JI, McDevitt HO: HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987;329:599–604.
18.
Anderson MS, Bluestone JA: The NOD Mouse: a Model of Immune Dysregulation. Annu Rev Immunol 2005;23:447–485.
19.
Nishimoto H, Kikutani H, Yamamura K, Kishimoto T: Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice. Nature 1987;328:432–434.
20.
Uehira M, Uno M, Kurner T, Kikutani H, Mori K, Inomoto T, Uede T, Miyazaki J, Nishimoto H, Kishimoto T, et al: Development of autoimmune insulitis is prevented in E alpha d but not in A beta k NOD transgenic mice. Int Immunol 1989;1:209–213.
21.
Lund T, O’Reilly I, Hutchings P, Kanagawa O, Simpson E, Gravely R, Chandler P, Dyson J, Picard JK, Edwards A, Kioussis D, Cooke A: Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain. Nature 1990;345:727–729.
22.
Wherrett DK, Singer SM, McDevitt HO: Reduction in diabetes incidence in an I-Ag7 transgenic nonobese diabetic mouse line. Diabetes 1997;46:1970–1974.
23.
Wong FS, Wen L: The study of HLA class II and autoimmune diabetes. Curr Mol Med 2003;3:1–15.
24.
Bell GI, Horita S, Karam JH: A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984;33:176–183.
25.
Lucassen AM, Julier C, Beressi JP, Boitard C, Froguel P, Lathrop M, Bell JI: Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nat Genet 1993;4:305–310.
26.
Owerbach D, Gabbay KH: Localization of a type I diabetes susceptibility locus to the variable tandem repeat region flanking the insulin gene. Diabetes 1993;42:1708–1714.
27.
Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE, Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F, NerupJ, BouzekriN, Cambon-ThomsenA, RønningenKS, BarnettAH, BainSC, ToddJA: Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 1995;9:284–292.
28.
Undelien DE, Bennett ST, Todd JA, Akselsen HE, Ikaheimo I, Reijonen H, Knip M, Thorsby E, Ronningen KS: Insulin gene region encoded susceptibility to IDDM maps upstream of the insulin gene. Diabetes 1995;44:620–625.
29.
Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG, Polychronakos C: Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leucocytes. J Autoimmun 1996;9:397–403.
30.
Bennett ST, Wilson AJ, Cucca F, Nerup J, Pociot F, McKinney PA, Barnett AH, Bain SC, Todd JA: IDDM2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. J Autoimmun 1996;9:415–421.
31.
Derbinski J, Schulte A, Kyewski B, Klein L: Promiscuous gene expression in medullary thymic epithelial cells mirror the peripheral self. Nat Immunol 2001;2:1032–1039.
32.
Heath WR, Allison J, Hoffmann MW, Schonrich G, Hammerling G, Arnold B, Miller JF: Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature 1992;359:547–549.
33.
Smith KM, Olson DC, Hirose R, Hanahan D: Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. Int Immunol 1997;9:1355–1365.
34.
Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, Wickramasinghe S, Colle E, Polychronakos C: Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997;15:289–292.
35.
Pugliese A, Zeller M, Fernandez A, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD: The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15:293–297.
36.
Chentoufi AA, Polychronakos C: Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance. The mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 2002;51:1383–1390.
37.
Faideau B, Briand J, Lotton C, Tardivel I, Halbout P, Jami J, Elliott, JF, Krief P, Muller S, Boitard C, Carel J: Expression of preproinsulin-2 gene shapes the immune response to preproinsulin in normal mice. J Immunol 2004;172:25–33.
38.
Thebault-Baumont K, Dubois-Laforgue D, Krief P, Briand JP, Halbout P, Vallon-Geoffroy K, Morin J, Laloux V, Lehuen A, Carel JC, Jami J, Muller S, Boitard C: Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003;111:851–857.
39.
Vafiadis P, Ounissi-Benkalha H, Palumbo M, Grabs R, Rousseau M, Goodyer CG, Polychronakos C: Class III alleles of the variable number of tandem repeat insulin polymorphism associated with silencing of thymic insulin predispose to type 1 diabetes. J Clin Endocrinol Metab 2001;86:3705–3710.
40.
Vafiadis P, Bennett ST, Todd JA, Grabs R, Polychronakos C: Divergence between genetic determinants of IGF2 transcription levels in leukocytes and of IDDM2-encoded susceptibility to type 1 diabetes. J Clin Endocrinol Metab 1998;83:2933–2939.
41.
Vafiadis P, Grabs R, Goodyer CG, Colle E, Polychronakos C: A functional analysis of the role of IGF2 in IDDM2-encoded susceptibility to type 1 diabetes. Diabetes 1998;47:831–836.
42.
Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, Larrad MT, Rios MS, Chow CC, Cockram CS, Jacobs K, Mijovic C, Bain SC, Barnett AH, Vandewalle CL, Schuit F, Gorus FK, Tosi R, Pozzilli P, Todd JA: The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Hum Mol Genet 1996;5:1075–1080.
43.
Marron MP, Zeidler A, Raffel LJ, Eckenrode SE, Yang JJ, Hopkins DI, Garchon HJ, Jacob CO, Serrano-Rios M, Martinez Larrad MT, Park Y, Bach JF, Rotter JI, Yang MC, She JX: Genetic and physical mapping of a type 1 diabetes susceptibility gene (IDDM12) to a 100-kb phagemid artificial chromosome clone containing D2S72-CTLA4-D2S105 on chromosome 2q33. Diabetes 2000;49:492–499.
44.
Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, DiGenova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506–511.
45.
Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C: A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002;277:46478–46486.
46.
Anjos SM, Tessier MC, Polychronakos C: Association of the cytotoxic T lymphocyte-associated antigen 4 gene with type 1 diabetes: evidence for independent effects of two polymorphisms on the same haplotype block. J Clin Endocrinol Metab 2004;89:6257–6265.
47.
Anjos S, Polychronakos C: Mechanisms of genetic susceptibility to type I diabetes: beyond HLA. Mol Genet Metab 2004;81:187–195.
48.
Anjos SM, Shao W, Marchand L, Polychronakos C: Allelic effects on gene regulation at the autoimmunity-predisposing CTLA4 locus: a re-evaluation of the 3′+6230G>A polymorphism. Genes Immun 2005;6:305–311.
49.
Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS, Comings D, Mustelin T: A functional variant of lymphoid tyrosine phosphatase is associated with type 1 diabetes. Nat Genet 2004;36:337–338.
50.
Qu H, Tessier MC, Hudson TJ, Polychronakos C: Confirmation of the association of the R620W polymorphism in the protein tyrosine phosphatase PTPN22 with type 1 diabetes in a family based study. J Med Genet 2005;42:266–270.
51.
Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM, Vella A, Nutland S, Rance HE, Maier L, Barratt BJ, Guja C, Ionescu-Tirgoviste C, Savage DA, Dunger DB, Widmer B, Strachan DP, Ring SM, Walker N, Clayton DG, Twells RC, Gough SC, Todd JA: Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004;53:3020–3023.
52.
Onengut-Gumuscu S, Ewens KG, Spielman RS, Concannon P: A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type I diabetes in multiplex families. Genes Immun 2004;5:678–680.
53.
Ladner MB, Bottini N, Valdes AM, Noble JA: Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes. Hum Immunol 2005;66:60–64.
54.
Hill RJ, Zozulya S, Lu YL, et al: The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp Hematol 2002;30:237–244.
55.
Cohen S, Dadi H, Shaoul E, et al: Cloning and characterization of a lymphoid-specific inducible human protein tyrosine phosphatase, Lyp. Blood 1999;93:2013.
56.
Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan AC: PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 2004;303:685–689.
57.
Cloutier JF, Veillette A: Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999;189:111–121.
58.
Polychronakos C: Animal models of spontaneous autoimmune diabetes: notes on their relevance to the human disease. Curr Diab Rep 2004;4:151–154.
59.
Polychronakos C: Impact of the Human Genome Project on pediatric endocrinology. Horm Res 2003;59:55–65.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
